"We expect phase three of the clinical trial to be completed at the end of November, at which point the word will pass to the regulatory agencies. The problem is being able to get to the end of the tests without adverse events occurring. If so, the regulatory agencies will take 3-4 weeks and the first 20-30 million doses will be delivered to the EU by the end of the year ".
This was stated on Radio Cusano Campus by Piero Di Lorenzo, president and CEO of Irbm Pomezia, regarding the Oxford-Irbm-AstraZeneca anti-Covid vaccine candidate.
For the vaccine, Di Lorenzo explained, the normal times "could be 6-8 months, but in such an important situation I think that the regulatory agencies will try to reduce the time to give an answer within a few weeks. This does not mean that the vaccine will not be safe. The times that can be shortened in fact are those of the bureaucracy, of the normal practice of the bureaucratic process. While all the times due to scientific checks will be strictly maintained ".
In fact, he adds, "there is no multinational willing to put its credibility and its scientific reputation on the line to shorten the terms of an evaluation beyond what is allowed, it would be absurd. This is why it is a topic on which one can be more than sure" .
If all goes well, therefore, the regulatory agencies "will take 3-4 weeks and the first 20-30 million doses will be delivered to the EU by the end of the year. But if instead of taking 4 weeks, they will take twice as much then it will arrive in January. Stick to the discourse if it will be the end of the year or the beginning of January - he commented - I see it more as a theoretical question than with practical implications ".
The people, Di Lorenzo concluded, "want to understand if in certain times we will all be able to have a tool available to combat the pandemic and to return to a minimum of normal life from a social, but above all economic point of view".
To date, vaccine testing is proceeding in the best way
"I can say that at present everything is proceeding in the best way and there is no evidence that suggests contraindications from the point of view of age and pathologies".
This was stated on Radio Cusano Campus by Piero Di Lorenzo, president and CEO of Irbm Pomezia, regarding the Oxford-Irbm-AstraZeneca anti-Covid vaccine candidate.
As for the Financial Times' indiscretion regarding the robust immune response in elderly people, "this is an indiscretion because - he notes - nothing has yet been published on phase three. I would avoid commenting on the rumors".
